Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7557692 | 0.87 | ENPP2 (0.46) | MAOBSLC2A1ENPP2PPARGPTPN1 | |
| SCHEMBL7557088 | 0.86 | SLC2A1 (0.45) | MAOBSLC2A1ENPP2PPARGPTPN1 | |
| SCHEMBL7553259 | 0.86 | PTPN1 (0.45) | MAOBSLC2A1ENPP2PTPN1MEN1 | |
| SCHEMBL7556297 | 0.83 | SLC2A1 (0.44) | MAOBSLC2A1PPARGPTPN1MEN1 | |
| SCHEMBL7559213 | 0.77 | PTPN1 (0.40) | ENPP2PPARGPTPN1ALOX5MEN1 | |
| SCHEMBL7556493 | 0.77 | PPARG (0.42) | SLC2A1PPARGPTPN1ALOX5MEN1 | |
| SCHEMBL5470545 | 0.76 | PTPN1 (0.48) | PPARGPTPN1MEN1KMT2ALMNA | |
| SCHEMBL5470542 | 0.76 | PTPN1 (0.48) | PPARGPTPN1MEN1KMT2ALMNA | |
| SCHEMBL7554795 | 0.75 | ACHE (0.47) | PPARGPTPN1ALOX5MEN1KMT2A | |
| SCHEMBL7559696 | 0.74 | AMY1A (0.52) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | CHIN ALLISON C (US) | 2002-08-22 | — | — | US | disclosed |
| US-6372742-B1 | TELOMERASE ENZYME INHIBITORS AND ANTICANCER AGENTS | GERON CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-1109808-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002394-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | TERT, INMT, POT1 | MAOB 858/4885SLC2A1 4766/4885ENPP2 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.